Article Text

Download PDFPDF
EP818 Primary debulking surgery versus primary neoadjuvant chemotherapy with or without interval debulking surgery for advanced stage ovarian cancer: a single institute study
  1. YY Chen,
  2. YC Ou and
  3. H Lin
  1. Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan


Introduction/Background Neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) has been recommended as an alternative treatment for selected patients with advanced-stage epithelial ovarian cancer (EOC). The aim of present study was to compare clinical outcomes of primary debulking surgery (PDS) versus NACT with or without IDS in a single institute of women with advanced-stage EOC.

Methodology Retrospective cohort study of women with stage IIIC(T3cN0-1) and IV EOC diagnosed between 2008 and 2016 treated at Kaohsiung Chang Gung Memorial Hospital. Patients who underwent PDS and NACT were identified. The Kaplan-Meier method was used to compare progression-free (PFS) and overall survival (OS) data.

Results A total of 143 newly diagnosed stage IIIC (T3cN0-1)and IV EOC patients were included in the final analysis. 92 women (64.3%) underwent PDS, 33 (23.1%) underwent NACT-IDS, and 18 (12.6%) received chemotherapy alone. The patients who received chemotherapy alone had significantly lower PFS of 4 months and OS of 28 months compared to PDS (PFS:13 months; OS:46 months) and NACT-IDS (PFS: 14 months; OS:28 months) groups, respectively.

Conclusion NACT-IDS did not improve PFS and OS compared to PDS in advanced-stage EOC. Patients received chemotherapy alone had the lowest PFS and OS compared to PDS and NACT-IDS groups.

Disclosure Nothing to disclose.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.